COVID may cause hospitals’ bottom lines to bottom out—again

Leaders of hospitals and health systems should expect declines in patient volumes throughout the fall and winter.

In some areas the resulting business downturns may rival the low points of March and April, when the pandemic pummeled the healthcare economy.

So warns Kaufman Hall, which has issued a report showing provider institutions operating at a negative margin, –1.6%, in October before CARES Act funding is figured in.

Reviewing October data from around 900 hospitals across the country, the management consultancy also found:

  • Adjusted discharges fell 11.2% year to date, 9.3% year over year and 5.5% below budget.
  • Adjusted patient days decreased 7.7% YTD and 2.9% YOY, but were up 1.4% above budget.
  • Operating room minutes fell 11.7% YTD and 5.6% YOY.

Hardest hit of all were emergency departments, which saw volume dips of 16% both YTD and YOY in October.

“The coming months will be critical for our nation’s hospitals, with the virus expected to continue its rapid spread as families gather for the holidays and activities move increasingly indoors with the onset of colder weather across much of the country,” the report authors comment.

Click here for the full report.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.